In a controlled trial involving men with type 2 diabetes, weekly semaglutide administration for 6 months resulted in statistically significant decreases in circulating TNF-α and IL-6, demonstrating direct anti-inflammatory benefits [219]. Here, TNF is linked to type 2 diabetes mellitus.